• IPO comprises a fresh issue of 45,84,000 equity shares with a face value of Rs. 10 each
• In December 2023, Nephro Care India Limited successfully closed the pre-IPO funding round, which saw the participation of banking veteran and former chairman of HDFC Ltd, Deepak Parekh, Chairman of HDFC Securities Bharat Shah, and Rajendra Agarwal, Founder and MD of Macleods Pharmaceuticals, among others.
• The Kolkata-headquartered healthcare provider is a one-stop treatment centre, that offers a wide range of clinical and lifestyle solutions and renal insufficiency treatment to patients
• NCIL intends to utilise net proceeds from the IPO to set up a multi-speciality hospital ‘Vivacity Multi Speciality Hospital’ at Madhyamgaram in Kolkata, West Bengal, and for general corporate purposes
• Nephro Care India Limited posted a revenue of Rs. 19.90 crore in the first nine months of FY2023-24, compared to a revenue of Rs. 17.09 crore in FY2022-23
• Corporate Capital Ventures is the Book Running Lead Manager, and Bigshare Services Private Limited is the Registrar for the issue

Nephro Care India Limited (“NCIL” or “The Company”), a leading multi-speciality healthcare provider in East India, announced the filing of its Draft Red Herring Prospectus (DRHP) with NSE Emerge. The company’s initial public offering comprises a fresh issuance of 45,84,000 Equity Shares, each with a face value of Rs. 10.

Corporate Capital Ventures Private Limited is the sole Book Running Lead Manager to the Issue, and Bigshare Services Private Limited is the Registrar. Corporate Capital Ventures has completed a string of successful SME IPOs in the recent months, including Trust Fintech, Creative Graphics, Alpex Solar, Rockingdeals, Accent Microcell, Oriana Power, Droneacharya and Crayons Advertising, among others.

In December 2023, Nephro Care India Limited successfully closed the pre-IPO funding round, which saw the participation of banking veteran and former chairman of HDFC Ltd, Deepak Parekh, chairman of HDFC Securities Bharat Shah, and Rajendra Agarwal, Founder and MD of Macleods Pharmaceuticals, among others.

The Kolkata-headquartered healthcare provider offers a wide range of clinical and lifestyle solutions and renal insufficiency treatment to patients. The treatment framework at NCIL covers the entire range of lifestyle, physiological and spiritual aspects of wellness.

NCIL currently provides healthcare services to around 900 chronic kidney disease (CKD) patients every month. It engages over 5 permanent doctors along with 10 visiting consultants led by 70 experienced professionals at its flagship Salt Lake clinic, which is spread over 5,352 sq. ft., and two satellite clinics at Salt Lake (HB 113) and Chandannagar, near Kolkata. The company is also in the process of opening three more satellite clinics at Alipurduar and Shyambazar in West Bengal and Balasore in Odisha.

According to DRHP, NCIL intends to utilise net proceeds from the IPO to set up a multi-speciality hospital, ‘Vivacity Multi Speciality Hospital’, at Madhyamgaram in Kolkata, West Bengal, and for general corporate purposes. The new hospital will be a unit of Nephro Care India Limited and is proposed to include 100 inpatient beds, including a 30-bed Critical Care unit having ICU, HDU, RTU and NICU facilities. Vivacity will offer treatment services in various disciplines such as cardiology, medical oncology, gastroenterology, gynaecology and many others, including an advanced renal transplant unit in East India.

Nephro Care operates on a multidimensional patient engagement framework comprising programs and facilities such as Mukti, Home Dialysis, Home Care and Diagnostics. While Mukti takes care of the overall well-being of the patient and improves the quality of life through a blend of modern medicine and ancient yogic wisdom, Home Dialysis offers dialysis at the comfort of homes to CKD patients who are unable to visit the dialysis centres, and “Home Care” services ensure clinical & lifestyle support beyond clinics to take care of all collateral medical needs of the patients.

NCIL’s clinics are operated on a ‘hub-and-spoke’ model, where each clinic is independent and individually well-equipped with skilled healthcare professionals and advanced infrastructure to serve the healthcare needs of the patients and ensure their rehabilitation.

Nephro Care was founded in the year 2014 by one of the leading nephrologists in India, Dr. Pratim Sengupta, in Kolkata, with the objective of providing comprehensive medical services for renal patients. With over 20 years of active clinical experience, Dr. Sengupta, has successfully performed more than 1,000 kidney transplants till now and is a pioneer in holistic renal care through a combination of clinical intervention, yoga and lifestyle support. Dr. Sengupta has been awarded the “Bharat Jyoti Award” for meritorious services, outstanding achievement and remarkable role by the India International Friendship Society in 2019.

NCIL posted a revenue of Rs. 19.90 crore and earned a profit (PAT) of Rs. 3.4 crore during the first nine months of FY 2023-24, compared to a revenue of Rs. 17.09 crore, with a profit (PAT) of Rs. 1.94 crore in FY 2022-23.

For more information, please visit: https://www.nephrocareindia.com/

Disclaimer: NEPHRO CARE INDIA LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the DRHP with the NSE Emerge. The DRHP is available on the website of BRLM and the website of NSE. Any potential investors should note that investment in equity shares involves a high degree of risk, and for details relating to the same, please refer to the DRHP, including the section titled “Risk Factors”, beginning on page 28.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act) or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. state securities laws. The Equity Shares are being issued and sold outside the United States in ‘offshore transactions in reliance on Regulation “S* under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.